Trial record 3 of 7 for:    pazopanib GIST

SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor)

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified March 2016 by Sarcoma Alliance for Research through Collaboration
Information provided by (Responsible Party):
Sarcoma Alliance for Research through Collaboration Identifier:
First received: January 15, 2015
Last updated: March 28, 2016
Last verified: March 2016
This study evaluates the combination of trametinib and pazopanib in patients with advanced gastrointestinal stromal tumors (GIST).

Condition Intervention Phase
Gastrointestinal Stromal Tumors
Drug: Pazopanib
Drug: Trametinib
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: SARC029: Phase II Pilot Study of Trametinib in Combination With Pazopanib in Patients With Metastatic or Local-regionally Recurrent GIST (Gastrointestinal Stromal Tumor) Refractory or Intolerant to at Least Imatinib and Sunitinib

Resource links provided by NLM:

Further study details as provided by Sarcoma Alliance for Research through Collaboration:

Primary Outcome Measures:
  • Disease Control Rate (DCR) [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
    Disease Control Rate (DCR) is the percentage of patients who have achieved complete response, partial response and stable disease to study treatment

Secondary Outcome Measures:
  • Progression Free Survival (PFS) [ Time Frame: Up to 12 months ] [ Designated as safety issue: No ]
    Date of first dose of drug to date of imaging demonstrating disease progression.

  • Overall Survival (OS) [ Time Frame: up to 10 years ] [ Designated as safety issue: No ]
    Time from first date of drug administration to date of death from any cause

  • Number and type of adverse events [ Time Frame: up to 2 years ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 45
Study Start Date: January 2017
Estimated Primary Completion Date: January 2020 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Trametinib with Pazopanib
Participants will take pazopanib (800mg) and trametinib (2mg) by mouth daily for a 28 day cycle.
Drug: Pazopanib
A kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma and advanced soft tissue sarcoma who have receive prior chemotherapy.
Other Name: Votrient
Drug: Trametinib
A kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test.
Other Name: Mekinist

Detailed Description:
Trametinib and pazopanib are independently approved for other cancers. Both drugs work to inhibit tumor development in different ways. Combining these drugs may lead to improved disease control. The purpose of this study is to evaluate the effect of the combination of both drugs on advanced gastrointestinal stromal tumors.

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria includes:

  • Age ≥ 18 years
  • Histologically confirmed diagnosis of advanced GIST
  • ECOG performance status of 0-1
  • Measurable disease as per modified RECIST 1.1
  • Prior disease progression on at least imatinib and sunitinib. Maximum of 3 prior kinase inhibitors allowed for treatment of advanced disease. Patients with prior exposure to pazopanib or MEK inhibitors are not eligible.
  • Adequate organ systems function within 14 days (and 72 hours) prior to start of protocol therapy
  • Patients must provide written informed consent prior to performance of study-specific procedures or assessments and must be willing to comply with treatment and follow-up.
  • Women of childbearing potential must have a negative urine or blood pregnancy test within 7 days of Cycle 1 Day 1. Fertile men and women of childbearing potential must agree to use effective contraception as defined in Section 7 during the study and for 4 months following the last dose of study drugs in both sexes.
  • Life expectancy of ≥ 3months

Exclusion Criteria includes:

  • Prior malignancy.
  • Central nervous system (CNS) metastases at baseline, with the exception of those patients who have previously-treated CNS metastases (surgery +/- radiotherapy, radiosurgery, or gamma knife) and who meet both of the following criteria:

are asymptomatic and have no requirement for steroids or enzyme-inducing anticonvulsants in at least 3 months prior to screening.

  • Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding
  • Clinically significant gastrointestinal abnormalities that may affect absorption of investigational product
  • QTcB interval > 480 msec
  • History of one or more of the following cardiovascular conditions within the past 6 months:

Cardiac angioplasty or stenting Myocardial infarction Unstable angina Coronary artery bypass graft surgery Symptomatic peripheral vascular disease Class II, III, or IV congestive heart failure, as defined by the New York Heart Association (NYHA) Uncontrolled arrhythmias

  • Poorly controlled hypertension [defined as systolic blood pressure (SBP) of ≥ 140 mm Hg or diastolic blood pressure (DBP) of ≥ 90 mmHg].
  • History of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months.
  • Major surgery or trauma within 28 days prior to first dose of investigational product and/or presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement are not considered to be major surgery).
  • Evidence of active bleeding or bleeding diathesis.
  • Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels that increase the risk of pulmonary hemorrhage.
  • Recent hemoptysis (≥ 1/2 teaspoon of red blood within 8 weeks before first dose of study drug)
  • Any serious and or unstable pre-existing medical, psychiatric, or other condition that could interfere with the patient's safety, provision of informed consent, or compliance to study procedures.
  • Unable or unwilling to discontinue use of prohibited medications listed in Section 5.2.4 for at least 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of study drug and for the duration of the study.
  • Treatment with any of the following anti-cancer therapies:
  • Radiation therapy or tumor embolization within 14 days prior to the first dose of OR
  • Chemotherapy, immunotherapy, biologic therapy, investigational therapy or hormonal therapy within 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of study drug.
  • Ipilimumab must have been discontinued at least 8 weeks prior to initiation of treatment with trametinib
  • Administration of any non-oncologic investigational drug within 30 days or five half-lives (whichever is longer) prior to the first dose of study drug.
  • Any ongoing toxicity from prior anti-cancer therapy that is ≥ Grade 1 and/or that is progressing in severity, except alopecia.
  • Inability to swallow and retain oral medication
  • Known or suspected allergy or hypersensitivity to pazopanib, trametinib (GSK1120212), or excipients of the formulations given during the course of this trial.
  • History of interstitial lung disease or pneumonitis, intracardiac defibrillators, known HIV, active HBV or HCV infections, history of retinal vein occlusion, symptomatic or untreated leptomeningeal or brain metastases or spinal cord compression.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02342600

Contact: SARC OFFICE 734-930-7600

Sponsors and Collaborators
Sarcoma Alliance for Research through Collaboration
Principal Investigator: Kristen Ganjoo, MD Stanford University
  More Information

Additional Information:
Responsible Party: Sarcoma Alliance for Research through Collaboration Identifier: NCT02342600     History of Changes
Other Study ID Numbers: SARC029 
Study First Received: January 15, 2015
Last Updated: March 28, 2016
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Gastrointestinal Stromal Tumors
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Neoplasms by Histologic Type
Neoplasms, Connective Tissue
Neoplasms, Connective and Soft Tissue
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Protein Kinase Inhibitors processed this record on May 23, 2016